Yusra Shao, M.D.

Yusra F. Shao, M.D., is a recent graduate of the Hematology and Oncology fellowship at Karmanos Cancer Institute/Wayne State University where she served as chief fellow. Dr. Shao has a niche research interest in ocular melanoma and developing immune and cellular therapies. She is a member of the Cutaneous and Genitourinary Precision Oncology Alliance, and continues to publish and present her research work nationally. Dr. Shao is also passionate about promoting access to oncologic care to the underserved populations of the Detroit Metropolitan Area through her community outreach work. In her leisure time, she enjoys painting and exploring the outdoors.

Related News

June 27, 2025
IN THE NEWS: Getting a Second Opinion at Karmanos

105.9 KISS FM Getting a second opinion at Karmanos can provide patients with access to therapies and care they may not be able to receive elsewhere. Yusra Shao, M.D. , medical oncologist, member of the Genitourinary Oncology , Melanoma and Phase I Clinical Trials Multidisciplinary Teams, explained the benefits of patients deciding to get their care at Karmanos after they receive a second opinion, which includes access to clinical trials. Request a second opinion here . Your browser does not suppor...
Read More
May 12, 2025
IN THE NEWS: Muscle-Invasive Bladder Cancer Prognosis

Patient Power Bladder cancer that spreads into the muscle layer of the bladder is called muscle-invasive bladder cancer. Yusra Shao, M.D. , medical oncologist and member of the Genitourinary Oncology Multidisciplinary Team at Karmanos, described the recurrence rate of this disease and some treatment options that can improve outcomes. Read the article here .
Read More
December 12, 2024
IN THE NEWS – Immunotherapy for Bladder Cancer: A Promising Treatment

Patient Power Yusra Shao, M.D. , medical oncologist and member of the Genitourinary Oncology Multidisciplinary Team at Karmanos, explained how immune checkpoint inhibitors work when treating bladder cancer, and the response rate for this therapy. Read the article here .
Read More

Publications

Shao YF, DeBenedictis M, Yeaney G, Singh AD. Germ line BAP1 Mutation in Patients with Uveal Melanoma (UM) and Renal Cell Carcinoma (RCC). Ocular Oncology and Pathology 2021; 7:340–345 PMID: 34722490
Shao YF, Echegaray JJ, Singh N, Singh AD. Variability of Bad Prognosis in Uveal Melanoma. Ophthalmology Retina 2019
186–193. PMID: 31014770 3. Brewington BY, Shao YF, Davidorf FH, Cebulla CM. Brachytherapy for Patients with Uveal Melanoma: Historical Perspectives and Future Treatment Directions. Clinical Ophthalmology 2018; 12, 925–934. PMID: 29844657
Nagasaka M, Al-Share B, Shao YF, Sexton R, Al Hallak MN, Azmi AS, Sukari A. The Gut Microbiome and Cancer: A Comprehensive Review of Melanoma, Lung, Head and Neck and Gastrointestinal Tumors. Reference Collection in Food Science (planned for publication in the Comprehensive Gut Microbiota) Elsevier. Equal contribution as first author
Shao YF, Echegaray JJ, Singh AD. Metastatic Tumors of the Uvea. Intraocular Tumors 179–185 (Springer Singapore, 2019)

Provider Profile:
Yusra Shao, M.D.

Yusra Shao, M.D.

Cancers Treated

Locations

Karmanos Cancer Center

Education

School

Residency

Fellowships

Clinical Trials

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer

A first-in-human, open-label Phase 1/2 study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with relapsed/refractory advanced solid tumors.

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Subjects with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma

A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizu

An Open-label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations

A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cell renal cell carcinoma and other solid tumors

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma

Additional Info

Related News

IN THE NEWS: Getting a Second Opinion at Karmanos

IN THE NEWS: Muscle-Invasive Bladder Cancer Prognosis

IN THE NEWS – Immunotherapy for Bladder Cancer: A Promising Treatment

105.9 KISS FM | Getting a Second Opinion at Karmanos

WRIF | Dr. Yusra Shao and Meltdown Talk About Prostate Cancer Screening

Publications

Provider Profile: Yusra Shao, M.D.

Yusra Shao, M.D.

Locations

Karmanos Cancer Center

Provider Profile:
Yusra Shao, M.D.